CureVac Announces Senior Knowledge of Influenza and COVID-19 mRNA Vaccine Progression Programs
TÜBINGEN, Germany/ BOSTON, USA U. S. Bonds. January 30, 2023 CureVac N. V. (Nasdaq: CVAC), a global biopharmaceutical company introducing a new elegance of transforming messenger ribonucleic acid (mRNA)-based medicines, today announced positive extended initial knowledge of phase 1 clinical COVID-19 and seasonal influenza systems conducted in collaboration with GSK. Recently reported data focuses on teams of older adults in either indication. Detailed data can be found in the related presentation. changed the constructions of the COVID-19 flu vaccine and mRNA to the next level of clinical trials in 2023.
COVID-19 Program
The newly reported immunogenicity knowledge for CV0501 in the elderly (65 years of age) is in the fully recruited dose teams of 12, 25, and 50 μg, consisting of 10 dose-consistent subjects. On day 29 at the dose of 12 ug, CV0501 generated a post-recall and pre-recall proportion of serum neutralizing titers as opposed to BA. 1 of 13. 3.
While CV0501 encodes the Omicron BA. 1 variant, a Phase 2 clinical study, expected to begin later in 2023, will compare applicants for monovalent and/or bivalent vaccines designed to target clinically applicable variants.
Seasonal Influenza Program
The candidate vaccine for long-term clinical progression is expected to target all four influenza virus strains recently through WHO for influenza vaccines. A phase 1/2 review for multivalent vaccine applicants is expected to begin in mid-2023.
The preliminary effects discussed above in young adults for COVID-19 and influenza systems can be reviewed via the conference call and webcast fabrics archived on January 6, 2023, in the Events section of the CureVac homepage.
The CureVac/GSK collaboration on infectious diseases was first announced in July 2020. It focuses on the progression of new products based on the generation of CureVacs mRNA for other targets in the field of infectious diseases. The collaboration was expanded in February 2021 to also include a jointly developed COVID-19 vaccine. In 2022, companies expanded their progression strategy to test modified mRNA in addition to unchanged mRNA.
CV0501 is the first COVID-19 vaccine candidate applying chemically modified mRNA from the COVID-19 vaccine program developed in collaboration with GSK. It is based on the complex moment generation mRNA backbone of CureVac. CV0501 encodes the prefusion-stabilized full-length spike protein of the SARS-CoV-2 variant Omicron BA. 1 and is formulated with lipid nanoparticles (LNPs). As with all vaccine candidates applying the momentary generation mRNA backbone, CV0501 was designed with optimized non-coding regions in particular intended to offer enhanced mRNA translation for higher and longer protein expression compared to the first generation mRNA d. The ongoing Phase 1 dose escalation study is comparing the safety, reactogenicity, and immunogenicity of CV0501 as a booster vaccine in dose ranges from 12 to a prospective maximum of 200 mcg in predefined age groups of 18 to 64 and 65 years. It is planned to also test other cohorts at a 3 and 6 µg dose point. The study is taking place in the United States, Australia, and the Philippines and is expected to enroll up to 180 healthy participants. The knowledge provided in this press release represents the initial knowledge prior to the blocking of the knowledge base. Neutralizing antibodies were assessed by a pseudotyped neutralization control.
About FLU-SV-mRNA
FLU-SV-mRNA is the first influenza vaccine candidate to apply modified mRNA from the infectious disease mRNA vaccine program developed in collaboration with GSK. It is based on CureVac’s complex second-generation mRNA skeleton. The monovalent candidate encodes the A/Wisconsin/588/2019 (H1N1)pdm09 virus hemagglutinin (HA) protein based on World Health Organization (WHO) recommendations for the 2021–22 Northern Hemisphere season. The ongoing Phase 1 dose escalation study is comparing the safety, reactogenicity and immunogenicity of the monovalent candidate as a booster vaccine up to five doses ranging from 2 to 54 μg in predefined age teams aged 18 to forty-five years and 60 to 60 years. 80 years. Includes a licensed flu vaccine as an active comparator. The study is conducted in Canada, Spain and Belgium and is fully enrolled with 198 healthy participants. The lengthy data provided in this release represents data that was cleaned before the database crashes.
About CureVac
CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) generation, with more than 20 years of experience in the progression, optimization and manufacturing of this flexible biological molecule for medical purposes. The precept of the proprietary generation of CureVacs is the use of optimized mRNA as a knowledge carrier to instruct the human body to produce its own proteins capable of fighting a wide variety of diseases. In July 2020, CureVac entered into a collaboration with GSK to jointly expand new products in prophylactic vaccines against infectious diseases based on CureVac’s second-generation mRNA generation. This collaboration was later extended for the progression of second-generation COVID-19 vaccine applicants and engineered mRNA vaccine technologies. Based on its proprietary generation, CureVac has built a broad clinical portfolio in the spaces of prophylactic vaccines, cancer treatments, antiframework treatments, and treatment of rare diseases. CureVac N. V. is headquartered in Tübingen, Germany, with more than 1,000 employees at locations in Germany, the Netherlands, Belgium, Switzerland, and the United States. More data can be obtained at www. curevac. com.
Contact with CureVac Investor Relations
CureVac, Tübingen, Germany
Phone: 7071 9883-1298
M: 49 160 496949
sarah. fakih@curevac. com
CureVac Media Contact
Bettina Jödicke-Braas, Head of Communications
CureVac, Tübingen, Germany
Phone: 7071 9883-1087
CureVac Forward-Looking Statements
This press release contains statements that constitute forward-looking statements as that term is explained in the United States Private Securities Litigation Reform Act of 1995, with the addition of statements that express the opinions, expectations, ideals, plans, objectives, assumptions or assignments from CureVac N. V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc. , CureVac Swiss AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B. V. (corporate) in relation to long-term events or long-term effects, as opposed to statements that reflect past facts. The examples come with a discussion of the potential effectiveness of the company’s vaccine and remedy applicants and the company’s strategies, investment plans, expansion opportunities, and expansion of the market position. In some cases, you can identify those forward-looking statements through terminology such as anticipate, intend, believe, estimate, plan, seek, allocate or expect, possibly, will, might, intends or deserves, the negative of those terms. or similar explanations. Forward-looking statements are based on management’s existing ideals and assumptions and on data available to the company. However, such forward-looking statements are not promises of the Company’s performance, and you deserve not to place undue reliance on such statements. Forward-looking statements are subject to a large number of risks, uncertainties and other variable circumstances, including adverse global economic conditions and continued volatility in global money market positions, the ability to unload funding, the ability to conduct existing and preclinical studies. and in the long term. running clinical trials, timing, cost, and uncertainty of regulatory approval, reliance on third parties and collaborative partners, ability to market products, ability to manufacture products, imaginable adjustments to existing and proposed legislation, regulations, and government policies , competitive expansion pressures and business consolidation in the industry, effects of the COVID-19 pandemic on the business and operational effects of the business, ability to manage expansion, reliance on the body of key workers, reliance on intellectual asset protection, ability to ensure patient safety and fluctuations in operating effects due to the effect of exchange rates or other factors. These dangers and uncertainties could cause the statements to be inaccurate, and readers are cautioned not to place undue reliance on such statements. Many of these hazards are beyond the control of the company and may also cause their actual effects to differ materially from those that are expected to occur. Forward-looking statements included in this press release speak only as of the date hereof. The company does not assume any legal responsibility to update such statements or to publicly announce the effects of any revision of such statements to reflect long-term events or developments, except as required by law, and in particular disclaims it.
For more information, please see the company’s reports and filings with the U. S. Securities and Exchange Commission. USA (SEC). These documents may be received by visiting EDGAR at the SEC in www. sec. gov.